To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Not even another snowy lead-in to the weekend can stop the good news radiating from our Members like the sun we are all hoping to see very, very soon!
Congrats to our Members Bristol-Myers Squibb Company as well as Actavis on product approvals this week. See the detailed stories below.
Celgene Corporation unveiled its Corporate Responsibility Report, which highlights the numerous ways in which Celgene strives to make a difference in the world by working toward a healthy and sustainable future. Celgene is a leader in so many ways and their approach to corporate responsibility is a showcase of that leadership. BioNJ congratulates Celgene on helping to lead the way and is proud to have the company as a Market Maker Investor Member.
Other exciting news this week includes Cyclacel Pharmaceuticals’ announcement of its intention to offer shares of common stock in a public offering. Meanwhile Soligenix received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company’s Phase II study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. See below for news on PTC Therapeutics, Nephros and more!
The Academy at BioNJ also has many events coming up, with topics as diverse as Supply Chain Development for the Life Sciences Industry to The Essentials of Managed Care and Doing Deals, Funding and More!
Click here to read this week’s Weekender.